Suven gets product patents from Canada, Hong Kong

Patents are for new chemical entities, for treating disorders associated with neurodegenerative diseases

Suven Life Sciences announced today that it was granted one product patent from Canada and one product patent from Hong Kong corresponding to the new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases and were valid through 2032 and 2030 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and are being developed as therapeutic agents and are claimed to be useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficiency hyperactive disorder (ADHD), Huntington's disease, Parkinson's and Schizophrenia.

These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts, according to the company. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase 1 or Phase 2, it said.

"We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,"said Venkat Jasti, CEO of Suven.

Suven, a Hyderabad-based biopharmaceutical company, has 3 clinical stage compounds, a phase 2 undergoing candidate SUVN-502, Phase 1 completed candidate SUVN-G3031 and Phase 1 undergoing candidate SUVN-D4010 for Alzheimer's disease and Schizophrenia. In addition to that the company has ten internally discovered therapeutic drug candidates currently in pre-clinical stage of development targeting conditions such as ADHD, dementia, depression among other diseases.